Perimenopausal contraception: risk-reducing preferences of estetrol

• Mekan R. Orazov
• Victor E. Radzinsky
• Vasily V. Ermakov

Abstract

Perimenopause is a special period in a woman’s life when there is a high need for contraception, but at the same time, regular changes occur in many systems and organs associated with a growing estrogen deficiency. It is known that combined oral contraceptives remain one of the most effective methods of preventing unwanted pregnancy. But when it comes to contraception in older reproductive age, associated with an increase in a number of risks, safety and non-contraceptive effects aimed at reducing estrogen deficiency are of particular importance. Taking into account these factors, a new drug containing a unique estrogen - estetrol claims to be the optimal contraceptive.

Keywords:estetrol; drospirenone; hormonal contraception; perimenopause

REFERENCES

1. Finer L.B., Philbin J.M. Trends in ages at key reproductive transitions in the United States, 1951–2010. Womens Health Issues. 2014; 24 (3): e271–9. DOI: https://doi.org/10.1016/j.whi.2014.02.002 Epub 2014 Apr 12. PMID: 24721149; PMCID: PMC4011992.

2. National Medical Eligibility Criteria for Contraceptive Methods. ROAG, 2023. (in Russian)

3. Serova O.F., Sedaya L.V., Shutikova N.V. Pregnancy outcomes in women of later reproductive age. Doctor.Ru. 2020; 19 (1): 12–5. DOI: https://doi.org/10.31550/1727-2378-2020-19-1-12-15 (in Russian)

4. Gemzell-Danielsson K., Apter D., Zatik J., Weyers S., Piltonen T., Suturina L., et al. Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022; 129 (1): 63–71. DOI: https://doi.org/10.1111/1471-0528.16840 Epub 2021 Aug 9. PMID: 34245666; PMCID: PMC9290720.

5. Creinin M.D., Westhoff C.L., Bouchard C., Chen M.J., Jensen J.T., Kaunitz A.M., et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception. 2021; 104 (3): 222–8. DOI: https://doi.org/10.1016/j.contraception.2021.05.002 Epub 2021 May 15. PMID: 34000251.

6. Abot A., Fontaine C., Buscato M., Solinhac R., Flouriot G., Fabre A., et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014; 6 (10): 1328–46. DOI: https://doi.org/10.15252/emmm.201404112

7. Smirnova N.F., Fontaine C., Buscato M., Lupieri A., Vinel A., Valera M.C., et al. The activation function-1 of estrogen receptor alpha prevents arterial neointima development through a direct effect on smooth muscle cells. Circ Res. 2015; 117: 770–8.

8. Bagot C.N., Marsh M.S., Whitehead M., Sherwood R., Roberts L., Patel R.K., et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010; 8 (8): 1736–44. DOI: https://doi.org/10.1111/j.1538-7836.2010.03953.x Epub 2010 Jun 14. PMID: 20553380.

9. Coelingh Bennink H.J., Heegaard A.M., Visser M., Holinka C.F., Christiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric. 2008; 11 (suppl 1): 2–14. DOI: https://doi.org/10.1080/13697130701798692

10. Santen R.J., Yue W., Wang J.P. Estrogen metabolites and breast cancer. Steroids. 2015; 99 (pt A): 61–6. DOI: https://doi.org/10.1016/j.steroids.2014.08.003 Epub 2014 Aug 26. PMID: 25168343.

11. Yager J.D. Mechanisms of estrogen carcinogenesis: the role of E2/E1-quinone metabolites suggests new approaches to preventive intervention – a review. Steroids. 2015; 99 (pt A): 56–60. DOI: https://doi.org/10.1016/j.steroids.2014.08.006 Epub 2014 Aug 24. PMID: 25159108; PMCID: PMC4339663.

12. Gallez A., Blacher S., Maquoi E., et al. Estetrol combined to progesterone for menopause or contraception indication is neutral on breast cancer. Cancers (Basel). 2021; 13: 2486.

13. Singer C.F., Bennink H.J., Natter C., et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014; 35 (11): 2447–51.

14. Havrilesky L.J., Moorman P.G., Lowery W.J., et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122 (1): 139–47. DOI: https://doi.org/10.1097/AOG.0b013e318291c235

15. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet. 2008; 371 (9609): 303–14. DOI: https://doi.org/10.1016/S0140-6736(08)60167-1

16. Westhoff C., Britton J.A., Gammon M.D., Wright T., Kelsey J.L. Oral contraceptive and benign ovarian tumors. Am J Epidemiol. 2000; 152 (3): 242–6. DOI: https://doi.org/10.1093/aje/152.3.242

17. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Lindgren A., Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999; 10 (4): 277–84. DOI: https://doi.org/10.1023/A:1008945721786

18. Prokai L., Prokai-Tatrai K., Perje’si P., Simpkins J.W. Mechanistic insights into the direct antioxidant effects of estrogens. Drug Dev Res. 2006; 66: 118–25. DOI: https://doi.org/10.1016/j.steroids.2007.10.011

19. Tskitishvili E., Pequeux C., Munaut C., Viellevoye R., Nisolle M., Noël A., et al. Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study. J Endocrinol. 2017; 232 (1): 85–95. DOI: https://doi.org/10.1530/JOE-16-0434 Epub 2016 Oct 31. PMID: 27799463; PMCID: PMC5118942.

20. Smetnik P.V., Ilyina E.M. Estrogens and the central nervous system. Farmateka [Pharmateca]. 2013; (3): 8–9. (in Russian)

21. Apter D., Zimmerman Y., Beekman L., et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017; 22 (4): 260–7. PMID: 28641030.

22. Apter D., Zimmerman Y., Beekman L., et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016; 94 (4): 366–73. PMID: 27153745.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)